Misawa Sonoko
Department of Neurology, Graduate School of Medicine, Chiba University.
Brain Nerve. 2015 Nov;67(11):1421-8. doi: 10.11477/mf.1416200314.
Intravenous immunoglobulin (IVIg) and plasma exchange (PE) are of proven efficacy and are considered the standard therapy for Guillain Barré syndrome (GBS). However, some patients require artificial ventilation during the acute phase and experience long-lasting neurological deficits or symptoms. Currently, there is no established therapeutic intervention for GBS other than IVIg and PE, even though a number of compounds have been investigated. Clinical trials to investigate the efficacy and safety of a second IVIg or eculizumab are ongoing. Increased understanding of the pathophysiology of GBS is expected to contribute to the development of a novel therapeutic approach.
静脉注射免疫球蛋白（IVIg）和血浆置换（PE）已被证实有效，被认为是吉兰-巴雷综合征（GBS）的标准治疗方法。然而，一些患者在急性期需要人工通气，并经历长期的神经功能缺损或症状。目前，除了IVIg和PE之外，尚无针对GBS的确立的治疗干预措施，尽管已经研究了许多化合物。研究第二次IVIg或依库珠单抗疗效和安全性 的临床试验正在进行中。对GBS病理生理学的进一步了解有望促进新型治疗方法的开发。
